Jacobs Levy Equity Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-17,416
| Closed | -$7.9M | – | 1072 |
|
|
2025
Q4 | $7.9M | Sell |
17,416
-7,533
| -30% | -$3.25M | 0.03% | 336 |
|
|
2025
Q3 | $9.77M | Sell |
24,949
-26,007
| -51% | -$10.9M | 0.04% | 303 |
|
|
2025
Q2 | $22.7M | Sell |
50,956
-15,278
| -23% | -$7.04M | 0.09% | 198 |
|
|
2025
Q1 | $32.1M | Buy |
+66,234
| New | +$30.9M | 0.13% | 172 |
|
|
2024
Q1 | – | Sell |
-100,868
| Closed | -$41M | – | 1063 |
|
|
2023
Q4 | $41M | Sell |
100,868
-468,612
| -82% | -$173M | 0.21% | 115 |
|
|
2023
Q3 | $198M | Buy |
569,480
+19,010
| +3% | +$6.65M | 1.17% | 12 |
|
|
2023
Q2 | $194M | Sell |
550,470
-71,944
| -12% | -$24.2M | 1.12% | 11 |
|
|
2023
Q1 | $196M | Sell |
622,414
-13,578
| -2% | -$4.07M | 1.2% | 11 |
|
|
2022
Q4 | $184M | Buy |
635,992
+434,318
| +215% | +$132M | 1.24% | 9 |
|
|
2022
Q3 | $58.4M | Buy |
201,674
+62,213
| +45% | +$17.9M | 0.46% | 49 |
|
|
2022
Q2 | $39.3M | Buy |
139,461
+86,428
| +163% | +$23.1M | 0.3% | 86 |
|
|
2022
Q1 | $13.8M | Buy |
53,033
+17,769
| +50% | +$4.22M | 0.09% | 240 |
|
|
2021
Q4 | $7.74M | Sell |
35,264
-421,858
| -92% | -$82M | 0.05% | 348 |
|
|
2021
Q3 | $82.9M | Sell |
457,122
-172,787
| -27% | -$33.7M | 0.56% | 40 |
|
|
2021
Q2 | $127M | Buy |
629,909
+612,225
| +3,462% | +$128M | 0.86% | 12 |
|
|
2021
Q1 | $3.8M | Sell |
17,684
-114,685
| -87% | -$25.2M | 0.03% | 474 |
|
|
2020
Q4 | $31.3M | Buy |
132,369
+96,451
| +269% | +$22.1M | 0.27% | 95 |
|
|
2020
Q3 | $9.77M | Sell |
35,918
-18,465
| -34% | -$5.09M | 0.1% | 215 |
|
|
2020
Q2 | $15.8M | Buy |
+54,383
| New | +$14.7M | 0.17% | 147 |
|
|
2019
Q2 | – | Sell |
-92,342
| Closed | -$17M | – | 1036 |
|
|
2019
Q1 | $17M | Sell |
92,342
-230,348
| -71% | -$42.5M | 0.25% | 107 |
|
|
2018
Q4 | $53.5M | Buy |
322,690
+67,840
| +27% | +$11.8M | 0.94% | 10 |
|
|
2018
Q3 | $49.1M | Buy |
254,850
+30,060
| +13% | +$5.35M | 0.7% | 12 |
|
|
2018
Q2 | $38.2M | Buy |
224,790
+22,320
| +11% | +$3.46M | 0.6% | 17 |
|
|
2018
Q1 | $33M | Buy |
202,470
+5,930
| +3% | +$969K | 0.55% | 24 |
|
|
2017
Q4 | $29.5M | Buy |
196,540
+11,590
| +6% | +$1.72M | 0.52% | 29 |
|
|
2017
Q3 | $28.1M | Buy |
184,950
+9,096
| +5% | +$1.37M | 0.55% | 33 |
|
|
2017
Q2 | $22.7M | Sell |
175,854
-39,756
| -18% | -$4.79M | 0.48% | 50 |
|
|
2017
Q1 | $23.6M | Sell |
215,610
-24,140
| -10% | -$2.13M | 0.48% | 57 |
|
|
2016
Q4 | $17.7M | Buy |
239,750
+230,960
| +2,628% | +$18.8M | 0.34% | 86 |
|
|
2016
Q3 | $767K | Buy |
+8,790
| New | +$831K | 0.01% | 626 |
|
|
2014
Q2 | – | Sell |
-68,920
| Closed | -$4.87M | – | 940 |
|
|
2014
Q1 | $4.87M | Buy |
+68,920
| New | +$5.46M | 0.08% | 262 |
|
Other funds holding VRTX
VCM
VPM
Jacobs Levy Equity Management's VRTX Position: Q1 2026 in Review
Jacobs Levy Equity Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 17,416 shares — an estimated $7.9M sold.
Jacobs Levy Equity Management first reported a position in VRTX in Q1 2014 and held it in 31 quarters. The position peaked at $198M in Q3 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Jacobs Levy Equity Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Jacobs Levy Equity Management sold 17,416 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.9M.
- Jacobs Levy Equity Management first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 31 quarters.
- Jacobs Levy Equity Management's Vertex Pharmaceuticals position peaked at $198M in Q3 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.